SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today announced that Stephen A. Sherwin, M.D.,
chairman and chief executive officer of Cell Genesys, will present a
company update at the BIO CEO and Investor Conference in New York, New
York, on Monday, February 11, 2008 at 11:00 a.m. ET.
A live audio webcast of the presentation will be accessible through the
Investor Relations section of the Cell Genesys website,
http://www.cellgenesys.com. If you are unable to listen to the live
webcast, it will be archived on the site for at least 72 hours following
the presentation. To access the replay, go to the Investor Relations
section of the website.
Cell Genesys is focused on the development and commercialization of
novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms -- GVAX(TM) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and
a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell
Genesys continues to hold an equity interest in its former subsidiary,
Ceregene, Inc., which is developing gene therapies for neurodegenerative
disorders. Cell Genesys is headquartered in South San Francisco, CA and has
its principal manufacturing operation in Hayward, CA. For additional
information, please visit the company's website at
http://www.cellgenesys.com.
Contact:
Susan Ferris
Investor Relations
650-266-3200
SOURCE Cell Genesys
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Susan Ferris, Investor Relations of Cell
Genesys, +1-650-266-3200
|
